New inhaled therapy for scarred lungs enters first human tests
NCT ID NCT06181370
First seen Jan 07, 2026 · Last updated May 12, 2026 · Updated 16 times
Summary
This early-stage study tests an inhaled drug called AGMB-447 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. The main goal is to check safety and how the body handles the drug. About 145 participants will receive either the drug or a placebo via a nebulizer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IPF are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medicines Evaluation Unit Ltd. an IQVIA business
RECRUITINGManchester, M23 9QZ, United Kingdom
Conditions
Explore the condition pages connected to this study.